Figures & data
Table 1. Chemotherapeutic agents used in treatment of oral cancer.
Table 2. Potential salivary biomarkers used for detection of oral cancer.
Table 3. Examples of various nanocarriers used in oral cancer.
Table 4. Some patents in the area of oral anticancer drugs for oral therapeutics.
Balaji A, Pandey VP, Srinath MS, et al. Synthesis and characterization studies of cisplatin/hydroxypropyl-β-cyclodextrin complex. Pharmacologyonline. 2009;1:1135–1143. Agueros M, Ruiz-Gaton L, Vauthier C, et al. Combined hydroxypropyl-β-cyclodextrin and poly (anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci. 2009;38:405–413. Huang XX, Zhou CL, Wang H, et al. Pharmacokinetics, efficacy, and safety evaluation of docetaxel/hydroxypropyl-sulfobutyl-β-cyclodextrin inclusion complex. AAPS PharmSciTech. 2011;12:665–672. Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14:1310–1316. Oommen E, Tiwari SB, Udupa N, et al. Niosome entrapped β- cyclodextrin methotrexate complex as a drug delivery system. Indian J Pharmacol. 1999;31:279–284. Kavitha K, Srinivasa RA, Nalini CN. An investigation on enhancement of solubility of 5-fluorouracil by applying complexation technique - characterization, dissolution and molecular-modeling studies. J Applied Pharm Sci. 2013;3:162–166. Shrikhande S, Bajaj AN, Malhotra G, et al., inventors. Cipla Limited, King, Lawrence, assignee. Pharmaceutical compositions of polymeric nanoparticles. WO2016020697 A1. 2016 Feb 11. Lee SJ, Kim YH, Lee SH, et al., inventors. JW Pharmaceutical Corporation, assignee. Oxaliplatin nanoparticles and method for preparing same. US9393201 B2. 2016 Jul 19. Thaxton SC, Gordon LI, Mutharasan RK, et al., inventors. Northwestern University, assignee. Lipophilic nanoparticles for drug delivery. WO2015023797 A9. 2015 Mar 7. Severin E, Zykova I, Gulenko, V, et al., inventors. Unichempharm Ltd, Oy Filana Ltd, assignee. Docetaxel-based prolonged-release cancer treatment drug. US20150140109 A1. 2015 May 21. Braden ARC, Vishwanatha JK, inventors. University of North Texas Health Science Center at Fort Worth, assignee. Formulation of active agent loaded activated PLGA nanoparticles for targeted cancer nano-therapeutics. US9023395 B2. 2015 May 5. Desai NP, Shiong PS, Trieu V, inventors. Abraxis Bioscience, LLC, Los Angeles, CA, USA, assignee. Nanoparticle comprising rapamycin and albumin as anticancer agent. US 8,911,786 B2. 2014 Dec 16. Messersmith PB, Black KCL IV, Yi L, et al., inventors. Northwestern University, assignee. Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same. US8784895 B2. 2014 Jul 22. Severin E, Zykova I, Gulenko V, inventors. Oy Filana Ltd, assignee. Docetaxel-based prolonged-release cancertreatment drug. WO2013171382 A1. 2013 Nov 21. Maitra A, Pramanik D, inventors. The Johns Hopkins University, assignee. Smart polymeric nanoparticles which overcome multidrug resistance to cancer chemotherapeutics and treatment-related systemic toxicity. EP2648760 A2. 2013 Oct 16. Dash AK, Trickler WJ, inventors. Creighton University, assignee. Mucoadhesive nanoparticles for cancer treatment. US8242165 B2. 2012 Aug 14. Lee SJ, Kim YH, Lee SH, et al., inventors. Choongwae Pharma Corporation, assignee. Oxaliplatin nanoparticles and method for preparing same. WO2011034394 A2. 2011 Mar 24. Hong SH, Chung JH, inventors. Water-soluble organometallic nanoparticles and method for preparing the same. WO2007108618 A1. 2007 Sep 27. Nah JW, Jung TR, Chae SY, et al., inventors. Anti-cancer agent loaded hydrophobic bile acid conjugated hydrophilic chitosan oligosaccharide nanoparticles and preparation method thereof. WO2007086651 A1. 2007 Aug 2. Prasad NP, Roy I, Bergey EJ, et al., inventors. The Research Foundation of State University of New York, assignee. Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same. CA 2513759 A1. 2004 Aug 12. Liversidge GG, Liversidge E, Chester W, et al., inventors. Eastman Kodak Company, Rochester, NY, assignee. Surface modified anticancer nanoparticles. 1995. US005399363A.